-$0.81 Earnings Per Share Expected for Atossa Genetics Inc (ATOS) This Quarter

Equities analysts expect Atossa Genetics Inc (NASDAQ:ATOS) to announce earnings of ($0.81) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atossa Genetics’ earnings. Atossa Genetics posted earnings of ($2.04) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 60.3%. The business is expected to issue its next quarterly earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Atossa Genetics will report full-year earnings of ($3.72) per share for the current year, with EPS estimates ranging from ($4.29) to ($3.15). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.55) per share, with EPS estimates ranging from ($2.57) to ($2.53). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Atossa Genetics.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Monday, August 13th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($0.37) by ($2.53).

Several research firms recently commented on ATOS. Maxim Group set a $10.00 price objective on shares of Atossa Genetics and gave the stock a “buy” rating in a research report on Monday, May 14th. ValuEngine upgraded shares of Atossa Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Noble Financial set a $10.00 price objective on shares of Atossa Genetics and gave the stock a “buy” rating in a research report on Tuesday, May 15th.

Shares of Atossa Genetics stock traded up $0.01 on Monday, hitting $2.18. The company’s stock had a trading volume of 162,600 shares, compared to its average volume of 328,924. Atossa Genetics has a 52-week low of $2.01 and a 52-week high of $19.08.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply